Bonacia (Hefei) Pharmaceutical Technology

Established in 2004, Bonacia Pharmaceutical Technology, also known as Panacro, operates as a contract research organization (CRO) with a focus on clinical studies. The company provides comprehensive solutions for the clinical research and registration of chemical and biological drugs, as well as vaccines. Its business model is centered on delivering professional technical services to a client base of pharmaceutical companies, both domestic and international, across more than 20 major therapeutic fields. Panacro generates revenue by offering a full suite of services that span from Phase I to IV clinical trials, including data management, biostatistics, regulatory submissions, and commercialization support.

The company's service portfolio is designed to support the entire clinical development lifecycle. This includes early-phase strategy and planning, clinical trial management, data management, and statistical analysis. Panacro operates in accordance with international standards such as ICH-GCP and has established detailed standard operating procedures (SOPs) to ensure quality and efficiency. A key aspect of their operations is the close cooperation with a vast network of study sites in China. In recent years, Panacro has been integrating technology into its services, developing a cloud platform for clinical trials to enhance the efficiency of new drug R&D.

Significant milestones in the company's history include introducing strategic investment in 2016 to focus on innovative drugs and biologics. In 2018, Panacro acquired Ruijie Siyuan, which led to rapid performance growth. The company has expanded its operations significantly, with offices in 20 major provinces or cities in China and a team of over 800 professionals. In 2021, Panacro appointed Mr. Zhou, a professor from Duke University's School of Medicine, as its Chief Consulting Scientist to enhance its capabilities in clinical study design and international registration. The company has also been expanding its overseas business, including the establishment of Panacro Global InnovaSolution in the United States, and in 2023 applied for a GEM listing.

Keywords: Contract Research Organization, CRO, clinical trials, pharmaceutical R&D, drug development, vaccine clinical studies, IND application, NDA application, biostatistics, data management, regulatory affairs, clinical operations, oncology research, biologics, innovative drugs, clinical data management, Phase I-IV trials, pharmaceutical services, China clinical trials, global drug registration